What is the global market size of Infectious Disease Therapeutics Market?

Global Infectious Disease Therapeutics Market size was valued at USD 115 billion in 2021 and is poised to grow from USD 119.86 billion in 2022 to USD 166.97 billion by 2030, growing at a CAGR of 4.23% in the forecast period (2023-2030).

Who are the key vendors in the Global Infectious Disease Therapeutics Market?

Global infectious disease therapeutics market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'GlaxoSmithKline plc', 'Merck & Co.', 'Pfizer Inc.', 'Roche Holding AG', 'Novartis AG', 'Sanofi S.A.', 'Johnson & Johnson', 'AstraZeneca plc', 'AbbVie Inc.', 'Amgen Inc.', 'Bristol-Myers Squibb Company', 'Eli Lilly and Company', 'Gilead Sciences, Inc.', 'Bayer AG', 'Novo Nordisk A/S', 'Takeda Pharmaceutical Co. Ltd.', 'Biogen Inc.', 'Boehringer Ingelheim GmbH', 'Allergan plc', 'Celgene Corporation'.

Infectious Disease Therapeutics Market Size, Share, Growth Analysis, By Type (HIV, Hepatitis), By Treatment (Antibacterial, Antifungal Drugs), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35J2030 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 119 | Figures: 77

Infectious Disease Therapeutics Market News

In November 2022, NRG Therapeutics, Ltd. announced £16 million Series A for advancing mitochondrial therapeutics for Parkinson's and ALS.
In October 2022, Seres Therapeutics, Inc., a leading microbiome therapeutics company, announces that the FDA has accepted for priority review its Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection.

Infectious Disease Therapeutics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Infectious Disease Therapeutics Market size was valued at USD 116.8 billion in 2022 and is poised to grow from USD 121.71 billion in 2023 to USD 169.14 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031).

Global infectious disease therapeutics market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Gilead Sciences ', 'GlaxoSmithKline (GSK) ', 'F. Hoffmann-La Roche Ltd ', 'Merck & Co., Inc. ', 'Pfizer Inc. ', 'Novartis AG ', 'Johnson & Johnson (Janssen Pharmaceuticals) ', 'BioCryst Pharmaceuticals Inc. ', 'Boehringer Ingelheim GmbH ', 'AbbVie Inc. ', 'Sanofi ', 'AstraZeneca ', 'Bristol-Myers Squibb (BMS) ', 'Moderna, Inc. ', 'Regeneron Pharmaceuticals ', 'Vertex Pharmaceuticals ', 'Vir Biotechnology, Inc. ', 'Eli Lilly and Company ', 'Amgen Inc.'

Increased spending to enhance the penetration rate of infectious disease treatments, rising strategies to raise awareness about treatments and diagnosis of these conditions, and increased clinical trial research for the development of new drugs may drive the growth of global infectious disease therapeutics market over the forecast period.

Increasing prevalence of malaria disease in developing and underdeveloped countries including India, Africa, and other Southeast Asian countries, as well as increased research and development activities by key manufacturers and health care organisations, are all contributing to market development.

North America held the largest global infectious disease therapeutics market share in 2021 due to the region's growing rate of infectious diseases. This region's large geriatric population has emerged as a significant growth factor for the market during the forecast period. People's increased disposable income has also become an important growth factor. The government's provision of advanced health-care facilities in the form of reimbursement policies has greatly aided market growth. Moreover, the existence of key manufacturers in the United States, as well as an increase in clinical trials for the introduction of new treatment drugs, are estimated to generate to this region's large market share.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Infectious Disease Therapeutics Market Size, Share, Growth Analysis, By Type (HIV, Hepatitis), By Treatment (Antibacterial, Antifungal Drugs), By Region - Industry Forecast 2025-2032

Infectious Disease Therapeutics Market News

Infectious Disease Therapeutics Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Infectious Disease Therapeutics Market?

Who are the key vendors in the Infectious Disease Therapeutics Market?

What is the key driver of Infectious Disease Therapeutics Market?

What is the key market trend for Infectious Disease Therapeutics Market?

Which region accounted for the largest share in Infectious Disease Therapeutics Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300